Liaoning Chengda
Gortune Investment has started its investment in Liaoning Chengda since 2019 and became its largest shareholder in 2020. As of now, Gortune Investment holds 15.30% of Liaoning Chengda’s shares. On February 28, 2025, Gortune Investment obtained controlling interest in Liaoning Chengda through a board election.
Liaoning Chengda’s business is divided into four major segments: pharmaceuticals and healthcare, financial investment, supply chain service (trade), and energy development. The biopharmaceutical business is managed by its subsidiary, Chengda Biotechnology, which specializes in the R&D, production, and marketing of human vaccines. Its marketed products include rabies and Japanese encephalitis vaccines. The varieties under research mainly include vaccines for bivalent hemorrhagic fever with renal syndrome, meningococcal polysaccharide conjugate vaccine of group A and group C, tetravalent influenza virus split vaccine, Haemophilus influenzae type B conjugate vaccine, and inactivated hepatitis A vaccine. Chengda International mainly handles textile exports to Japan, the U.S., and Europe, and follows a strategy of cooperating with major international customers. Chengda Trade and Chengda Steel primarily engage in the domestic trade and import of bulk commodities such as oil, coal, steel, timber, and aquatic products, and the processing and re-export of incoming materials, striving to become organizers and managers of the supply chain.
